paediatrics Brussels 17

Group III Orbital RMS

N Chemotherapy

Radiotherapy Local Failure

D9602

77

VA

45 Gy

14%

IRS-III

71

VA

41.4-50.4Gy

16%

IRS-IV

50

VAC/VIE/VAE

50.4-59.4 Gy

4%

In the COG study (ARST0331), 45 Gy was used for Group III orbital RMS with the addition of cyclophosphamide to the chemotherapy regimen.

Breneman J et al. Int J Radiat Oncol Biol Phys 2012; 83:720-6